Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report

[ X ]

Tarih

2007

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Springer

Erişim Hakkı

info:eu-repo/semantics/closedAccess

Özet

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation between chromosomes 9 and 22. Imatinib mesylate is a potent and selective inhibitory of the BCR/ABL tyrosine kinase. Imatinib is a first choice of treatment of chronic phase CML. It has also shown activity in patients with CML in accelerated or blastic phases. However, the penetration of the drug and its active metabolites into the central nervous system (CNS) is poor. Therefore, the CNS is sanctuary site for malignant cells in patients treated with imatinib. Herein, we report a patient with CML in accelerated phase that developed central nervous system disease while on imatinib mesylate therapy.

Açıklama

Anahtar Kelimeler

Chronic Myeloid Leukemia, Blastic Phase, Imatinib Mesylate, Meningeal Leukemia

Kaynak

Journal of Neuro-Oncology

WoS Q Değeri

Q3

Scopus Q Değeri

Q1

Cilt

84

Sayı

1

Künye